Connor, Clark & Lunn Investment Management Ltd.

Position in NUVB — Nuvation Bio Inc.

CIK 1596800 VANCOUVER, A1

Position in NUVB

as of Mar 31, 2026 · filed May 11, 2026 Compact

Position Value

$5,181,337

+$3,461,035 QoQ

Shares Held

1,207,771

+529.1% QoQ

Ownership

0.347%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2022

11 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $703,286,486 across 100 Biotechnology names. NUVB ranks #38 (0.7% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	251,711	$112,399,029
2	IONS	Ionis Pharmaceuticals Inc	874,089	$65,635,343
3	ARWR	Arrowhead Pharmaceuticals, Inc.	836,981	$52,478,708
4	MIRM	Mirum Pharmaceuticals, Inc.	479,476	$44,293,992
5	REGN	Regeneron Pharmaceuticals, Inc.	32,164	$24,851,192
6	AXSM	Axsome Therapeutics, Inc.	134,792	$22,782,543
7	SRPT	Sarepta Therapeutics, Inc.	1,019,951	$22,194,133
8	TERN	Terns Pharmaceuticals, Inc.	384,681	$20,280,382

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$5,181,337	1,207,771	+529.1%	Shares	Sole	2026-05-11
2025-12-31	$1,720,302	191,998	-54.5%	Shares	Sole	2026-02-10
2024-12-31	$1,123,211	422,260	+6.4%	Shares	Sole	2025-02-10
2024-09-30	$908,525	396,736	+9.0%	Shares	Sole	2024-11-08
2024-06-30	$1,062,661	363,925	-4.8%	Shares	Sole	2024-08-09
2024-03-31	$1,391,135	382,180	+30.1%	Shares	Sole	2024-05-09
2023-12-31	$443,491	293,703	+6.3%	Shares	Sole	2024-02-09
2023-09-30	$370,073	276,174	+69.1%	Shares	Sole	2023-11-13
2023-06-30	$293,909	163,283	+191.3%	Shares	Sole	2023-08-10
2023-03-31	$93,034	56,045	-16.0%	Shares	Sole	2023-05-10
2022-12-31	$128,090	66,714	—	Shares	Sole	2023-02-10
No filing history on record for this holder in this stock.